{"disease":{"id":"active-secondary-progressive-multiple-sclerosis","name":"active secondary progressive multiple sclerosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04940065","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","phase":"","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05376579","title":"Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy","phase":"","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06890923","title":"Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Tiziana Life Sciences LTD","has_results":false},{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT06802328","title":"Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Tiziana Life Sciences LTD","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}